Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Infection
Published in: Infection 3/2004

01-06-2004 | Correspondence

Linezolid-Resistant Enterococcus faecium and Enterococcus faecalis Isolated from a Septic Patient: Report of First Isolates in Germany

Authors: E. Halle, J. Padberg, S. Rosseau, I. Klare, G. Werner, W. Witte

Published in: Infection | Issue 3/2004

Login to get access
Metadata
Title
Linezolid-Resistant Enterococcus faecium and Enterococcus faecalis Isolated from a Septic Patient: Report of First Isolates in Germany
Authors
E. Halle
J. Padberg
S. Rosseau
I. Klare
G. Werner
W. Witte
Publication date
01-06-2004
Publisher
Urban & Vogel
Published in
Infection / Issue 3/2004
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-004-3009-0

Other articles of this Issue 3/2004

Infection 3/2004 Go to the issue

Review

Staphylococcus aureus Infections in Injection Drug Users: Risk Factors and Prevention Strategies

Clinical and Epidemiological Study

Natural History of Acute Symptomatic Hepatitis Type C

Editorial

Towards a Better Understanding of HCV Transmission and Course of Infection

Case Report

Trimethoprim-Sulfamethoxazole Exacerbates Posthypoxic Action Myoclonus in a Patient with Suspicion of Pneumocystis jiroveci Infection

Clinical and Epidemiological Study

Update on Glycopeptide Use in German University Hospitals

What’s New in HIV/AIDS

How to Start Antiretroviral Therapy?
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits